CANF Can-Fite BioPharma Ltd Expected Profit

Corporate company logo of Can-Fite (CANF)

Expected net income for the business reflects the market consensus, with the figure standing at 0.00. The scaling growth of Can-Fite BioPharma (CANF) relies on future licensing payments amid current negative leverage. Key drivers include patent protection and the final stages of clinical trials for psoriasis and liver cancer drugs. The security of biosample supply chains guarantees steady progress in therapy development.

CANF - Can-Fite BioPharma Expected Net Income over the range 08/16/2024 - 03/30/2026

Analytical breakdowns for Can-Fite BioPharma Ltd (CANF)

- share price and consensus valuation forecast:
Stock Price Can-Fite BioPharma|CANF - Analyst Consensus Forecast
- market capitalization data:
Market Value Can-Fite BioPharma|CANF - Total Company Value
- company book value details:
Accounting Value per Share Can-Fite BioPharma|CANF - Accounting Value of Company|Market Value to Book Value Ratio canfite.com|CANF - Company Assets
- debt and solvency information:
Debt to Equity Can-Fite BioPharma|CANF - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Can-Fite BioPharma, Ltd.|CANF - Company Total Debt|Debt to Book Capitalization Ratio Can-Fite BioPharma|CANF - Long-Term Debt|Company Short-Term Debt Can-Fite BioPharma|Quick Liquidity canfite.com
- earnings and market ratios statistics:
CANF - Company Net Income|Projected Future Earnings Can-Fite BioPharma|CANF - Market Cap to Net Income Ratio|Projected Price to Earnings Can-Fite BioPharma Ltd.|CANF - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Can-Fite BioPharma|CANF - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Can-Fite BioPharma|CANF - Earnings per share for the last four quarters|Quarterly EPS earnings growth canfite.com|CANF - Earnings per share increase in current year|Earnings growth forecast for next year Can-Fite BioPharma
- sales and revenue indicators:
CANF - Company Total Revenue|Company Projected Revenue Can-Fite BioPharma|CANF - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Can-Fite BioPharma
Comprehensive company analysis:CANF, Can-Fite BioPharma
Core merchandise of Can-Fite BioPharma Ltd

The projected earnings of Can-Fite BioPharma (CANF) reflect the monetization potential of implementing software robots into the analysis of oncology targets. This metric is calculated through a synthesis of market quotes and expected cash flows across various time intervals. By analyzing the forward earnings chart, an investor assesses the business development vector and the precision of strategic planning. Growth in this indicator confirms the efficiency of data processing automation, while the stable dynamics of the metric attest to the long-term sustainability of the company.

Competitors of Can-Fite BioPharma

INCY (Incyte Corporation) - Projected Future Earnings|Projected Future Earnings hutch-med.com|Expected Profit Nuvation Bio (NUVB)|Expected Profit DAWN (Day One Biopharmaceuticals, Inc.)|Monopar Pharma - Future Profit|Expected Net Income INBX|IMAB - Expected Profit|Expected Net Profit fennecpharma.com|herontx.com (HRTX) - Expected Profit|Net Profit Forecast NVCT|CHRS (Coherus Biosciences) - Projected Future Earnings|Future Profit Corbus Pharmaceuticals, Inc. (CRBP)|Expected Profit Cardiff Oncology, Inc. (CRDF)|BYSI - Expected Net Profit|Expected Profit BioAtla BCAB|Lixte Biotechnology Holdings Inc. - Expected Profit|CTXR - Expected Profit|Expected Net Profit Cellectar Corp|BLRX: Projected Future Earnings|Projected Net Profit Aprea Therapeutics, Inc. APRE|Future Profit KZIA|Expected Net Profit Silexion SLXN|Future Profit NCNA (NuCana plc)|CMRX (Chimerix Inc) - Expected Net Income|Cyclacel Pharmaceuticals - Future Profit|Future Net Profit GTHX (G1 Therapeutics Inc.)|Kronos Bio - Projected Future Earnings|Expected Net Income KTRA (Kintara Therapeutics Inc)|ONCT: Projected Future Earnings|Expected Net Profit Portage Biotech Corp (PRTG)